CISPLATIN

作品数：604被引量：1584H指数：17
导出分析报告
相关领域：医药卫生更多>>
相关作者：曾慧慧王夔卢仁泉郭林李强更多>>
相关机构：华中科技大学四川大学北京大学卫生部更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金国家重点基础研究发展计划广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Chinese Journal of Cancer Researchx
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery:Final results of a phase Ⅱ trial
《Chinese Journal of Cancer Research》2025年第1期66-72,共7页Biao Fan Hao Su Lingqian Wang Xin Ji Yinan Zhang Ziyu Jia Ji Zhang Zhaode Bu Xiaojiang Wu 
supported by the National Nature Science Foundation of China(No.81402308);Science Foundation of Peking University Cancer Hospital(No.2021-24);Natural Science Foundation of Beijing Municipal(No.7242020);Science Foundation of Peking University Cancer Hospital(No.BJCH2025GG04);the National Nature Science Foundation of China(No.82173151).
Objective:The trial was designed to evaluate the efficacy of prophylactic hyperthermic intraperitoneal chemotherapy(HIPEC)with cisplatin for patients with locally advanced gastric cancer(LAGC).Methods:Between March 20...
关键词：Gastric cancer intraperitoneal chemotherapy CISPLATIN PROGNOSIS 
PhaseⅡstudy of induction chemotherapy followed by concurrent chemoradiotherapy with raltitrexed and cisplatin in locally advanced nasopharyngeal carcinoma被引量：5
《Chinese Journal of Cancer Research》2020年第5期665-672,共8页Yuan Wu Xueyan Wei Zilong Yuan Hongbin Xu Yanping Li Ying Li Liu Hu Guang Han Yu Qian Desheng Hu 
supported by The Radiation Therapy Major Project of the Ministry of Science and Technology of China(No.2016YFC0105711);supported partly by Natural Science Foundation of China(No.81401913)。
Objective:For locally advanced nasopharyngeal carcinoma(LA-NPC)patients,high incidences of distant metastases and severe treatment related toxicities are the main obstacles needed to be overcome.Raltitrexed,a specific...
关键词：Nasopharyngeal carcinoma RALTITREXED CISPLATIN induction chemotherapy concurrent chemoradiotherapy 
Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer:A phase II open-label clinical study被引量：9
《Chinese Journal of Cancer Research》2019年第2期339-348,共10页Shanshan Qin Hui Yu Xianghua Wu Zhiguo Luo Huijie Wang Si Sun Mingzhu Huang Jia Jin Zhonghua Tao Jie Qiao Yu Feng Jialei Wang Jianhua Chang 
Objective: The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel(nab-paclitaxel) plus cisplatin vs. gemcitabine plus cisplatin in patients with advance...
关键词：Albumin-bound paclitaxel CISPLATIN GEMCITABINE FIRST-LINE therapy ADVANCED non-small-cell lung cancer 
Microarray gene expression analysis of chemosensitivity for docetaxel,cisplatin and 5-fluorouracil(TPF)combined chemotherapeutic regimen in hypopharyngeal squamous cell carcinoma被引量：1
《Chinese Journal of Cancer Research》2017年第3期204-212,共9页Meng Lian Haizhou Wang Jugao Fang Jie Zhai Ru Wang Xixi Shen Yifan Yang Zhihong Ma Honggang Liu 
supported by grants of the Beijing Municipal Science&Technology Commission(No.Z141107002514003);Beijing Municipal Administration of Hospital Clinical Medicine Development of Special Funding Support(Code.XMLX201311);the Priming Scientific Research Foundation for the Junior Researcher in Beijing Tongren Hospital,Capital Medical University(2015-YJJ-ZZL-001)
Objective: To screen out a set of candidate genes which could help to determine whether patients with hypopharyngeal squamous cell carcinoma (HSCC) could benefit from docetaxel, cisplatin and 5-fluorouracil (TPF) indu...
关键词：MICROARRAY HSCC induction chemotherapy MAPK 
Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma被引量：18
《Chinese Journal of Cancer Research》2017年第2期149-155,共7页Liangze Zhang Weiwei Li Xiao Lyu Yan Song Yousheng Mao Shaoming Wang Jing Huang 
supported by the grant from Beijing Medical Award Foundation
Objective： No standard postoperative adjuvant chemotherapy has ever been established in node-positive esophageal squamous cell carcinoma （ESCC）. This is a study to explore the effect of postoperative paelitaxel （...
关键词：Esophageal cancer adjuvant chemotherapy SURGERY PACLITAXEL CISPLATIN 
Inhibition of PI3K/Akt/m TOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro被引量：11
《Chinese Journal of Cancer Research》2014年第5期564-572,共9页Yunlang Cai Xiaoqiang Tan Jun Liu Yang Shen Di Wu Mulan Ren Peilin Huang Dandan Yu 
supported by the National Natural Science Foundation of China (30973475);the Natural Science Foundation of Jiangsu Province (BK2012749);the Maternal and Child Health Research Project of Jiangsu Province (F201351)
The activation of the PI3K/AKT/m TOR pathway plays a key role in ovarian cancer tumorigenesis, progression and chemotherapy resistance. This study aimed to explore the possible mechanism that PI-103, a dual inhibitor ...
关键词：PI3K/AKT/m TOR CISPLATIN ovarian cancer 
Combination chemotherapy with paclitaxel,cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma:a multicenter prospective study被引量：8
《Chinese Journal of Cancer Research》2012年第4期291-298,共8页Xiao-Dong Zhang Yong-Qian Shu Jun Liang Feng-Chun Zhang Xue-Zhen Ma Jian-Jin Huang Li Chen Gen-Ming Shi Wei-Guo Cao Cheng-Ye Guo Lin Shen Mao-Lin Jin 
funded by Hospira Inc.,Australia
Objective： To evaluate the efficacy and toxicity of the combination regimen of paclitaxel, cisplatin and 5-FU （PCF） as first-line or second-line therapy in patients with advanced gastric and esophagogastric juncti...
关键词：Advanced gastric cancer esophagogastric junction （EGJ） ADENOCARCINOMA PACLITAXEL 
Expressions of Thymidylate Synthase, Thymidine Phosphorylase, Class Ⅲ β-tubulin, and Excision Repair Cross-complementing Group 1 Predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin被引量：22
《Chinese Journal of Cancer Research》2011年第4期288-294,共7页Ming Lu Jing Gao  Xi-cheng Wang  Lin Shen 
supported by the National "863" High‐Tech Res & Dev Program of China (No. 2006AA02A402);Beijing Municipal Science & Technology Commission Program "Optimization of pharmacotherapy and individual selection in gastric cancer" (No D101100050010023)
Objective: To evaluate the role of class III β-tubulin (TUBB3), thymidylate synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementing group 1 (ERCC1) in clinical outcome of advanced gastric...
关键词：Advanced gastric cancer TS/TP/TUBB3/ERCC1 CAPECITABINE PACLITAXEL CISPLATIN 
Phase I Study to Determine MTD of Docetaxel and Cisplatin with Concurrent Radiation Therapy for Stage Ⅲ Non-Small Cell Lung Cancer被引量：5
《Chinese Journal of Cancer Research》2011年第2期129-133,共5页You-quan Li An-hui Shi Fu-hai Li Rong Yu Guang-ying Zhu 
support by the grant of the National Natural Science Foundation of China (No. 30870738)
Objective： To evaluate the maximum tolerated dose （MTD） of docetaxel （DCT） and cisplatin （DDP） concurrently with three dimensional （3D） conformal radiotherapy or IMRT for patients with locally advanced non-sm...
关键词：Non–small-cell lung cancer Concurrent chemoradiotherapy Cisplatin docetaxel TOXICITY 
High Expression of ERCC1 Is a Poor Prognostic Factor in Chinese Patients with Non-small Cell Lung Cancer Receiving Cisplatin-based Therapy被引量：2
《Chinese Journal of Cancer Research》2010年第4期296-302,共7页Qing-zhi Guo Jie Wang Hua Bai Tong-tong An Meina Wu Jun Zhao Lu Yang Jian-chun Duan Yu-yan Wang Zhi-jie Wang 
Objective： to determine the role of excision repair cross-complementing group 1 gene （ERCC1） and ribonucleotide reductase subunit M1 （RRM1） expression in predicting response and survival in Chinese patients with ...
关键词：ERCC1 RRM1 NSCLC Platinum-based chemotherapy mRNA Realtime PCR 
全选清除导出
共3页<123>
检索报告 对象比较 聚类工具 使用帮助 返回顶部